key: cord-0966983-l22v8e6b
authors: Strom, Mark A.; Trager, Megan H.; Timerman, Dmitriy; Coromilas, Alexandra J.; Burris, Katy; Belsito, Donald V.; Eber, Ariel; Greenberg, Sophie; Husain, Sameera; Lewin, Jesse M.; Naka, Fludiona; Patrone, Christina C.; Coulon, Aaron; Cooper, Chelsea; Bartholomew, Frederick B.; Beck, Melissa; Dowd, Margaret L.; Ensslin, Courtney; Gallitano, Stephanie M.; Loesch, Eric; Malajian, Dana M.; Melnick, Laura; Niedt, George W.; Uwakwe, Laura N.; Vu, Ha Linh; Walther, Robert R.; Samie, Faramarz H.; Geskin, Larisa J.
title: Cutaneous findings in hospitalized and critically-ill patients with COVID-19: A case series of 15 patients
date: 2020-10-14
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.10.014
sha: e37d17067ca91c35175ccf1fbf1c4bfde03cc47e
doc_id: 966983
cord_uid: l22v8e6b

nan

chilblain, vesicles, urticaria, livedo, and multi-system inflammatory syndrome, as manifestations of Coronavirus Disease of 2019 . [1] [2] [3] [4] [5] Here, we report on the cutaneous findings observed in hospitalized COVID-19 positive patients at Columbia University Irving Medical Center (CUIMC) by the adult dermatology consult service between 3/25/2020 and 5/1/2020.

Cases were included if COVID-19 was most likely associated with or contributed to skin findings observed after other potential causes were excluded. While previous studies on the cutaneous manifestations of COVID-19 have focused primarily on outpatients and those with mild disease, 2,3 this study provides insights into the cutaneous manifestations of severe disease.

This study was approved by the Institutional Review Board at CUIMC.

Nine patients developed signs of acral ischemia, including duskiness, necrosis, and bulla ( Figure 1A) . Eight of these with acral ischemia required admission to the intensive care unit (ICU), and the location of ischemia included fingers, toes, ears, and genital skin (STable1). Two with severe lesions had a confirmed deep vein thrombosis, highlighting the potential for thrombotic events (Cases 7, 9).

Three patients developed livedo racemosa, one of whom had livedo as a presenting sign of COVID-19, and two who developed livedo during their hospitalization. One patient developed vesicles in association with his livedoid eruption (Case 10). All three required ICU admission and had evidence of coagulopathy (Cases 10,11,12; Figure 1B) .

Two patients developed evidence of bleeding diatheses. One, a critically-ill male in his 60s (Case 14) developed petechiae, with perivascular lymphocytic infiltrate with prominent red cell extravasation on biopsy. He was mildly thrombocytopenic (114x10 3 /uL) and had mild coagulopathy (PT/INR 14.7 seconds/1.2; aPTT 36.2 seconds and d-dimer 3.95 ug/mL). The other patient, a male in his 70s, developed purpura fulminans with areas of necrosis and superficial desquamation on the chest and axilla (Case 13). Laboratory data was consistent with disseminated intravascular coagulation, and ultimately, the patient expired.

Erythema multiforme (EM)-like lesions were observed in a woman in her 80s one week following discharge after treatment for COVID-19-associated pneumonia (Case 15). She had no other risk factors for development of EM-like lesions, including active HSV infection, and received no new medications in the last three days of her hospitalization or on discharge.

Interestingly, no pseudo-chilblain (Covid toes) was observed in the hospitalized patients evaluated. Pseudo-chilblain may be more strongly-associated with mild disease, or present after acute illness has resolved.

In summary, cutaneous manifestations in hospitalized COVID-19 patients are varied and are an important part of this potentially life-threatening illness. Findings in critically-ill patients may differ from findings in outpatients with mild disease. Limitations of our study include that cases were limited to a single institution, lack of histology on the majority of cases, and inability to establish the pathophysiologic role of SARS-CoV-2 in the reported skin diseases.

Additionally, less severe skin findings may not have required dermatology consultation. Further large-scale cohort studies with classification of histology are necessary to better describe both the frequency and etiology of these findings.

Cutaneous manifestations in COVID-19: a first perspective

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France

Shulman ST: Pediatric Coronavirus Disease-2019-Associated Multisystem Inflammatory Syndrome